Antibody show promise against multiple sclerosis

Written by Amy Bamford

Published recently in the New England Journal of Medicine, three clinical trials conducted by a team of international researchers have demonstrated that orcrelizumab, a humanized monoclonal antibody that depletes CD20+ B cells, can slow the progression of primary progressive multiple sclerosis (MS) and reduce new attacks in patients with relapsing remitting MS. These new findings are a promising breakthrough for the treatment of MS; however, further research is required to govern the drug’s long-term safety and efficacy. In one of the three clinical trials, researchers randomly assigned 732 patients with primary progressive MS to receive either ocrelizumab or a placebo....

To view this content, please register now for access

It's completely free